NASDAQ
12.52USD
+0.08 (+0.64%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
292.1M
P/E
—
EPS
—
Beta
-0.09
52W range
8.46-45
Day range
12.35–13.02
Open
12.48
Prev close
12.44
Volume
161.5K
Avg volume
91.2K
Dividend
0.00
IPO
2021-06-17
https://seekingalpha.com/article/4914802-lyell-immunopharma-undervalued-ahead-of-a-major-car-t-inflection · 6/13/2026+0.80
https://www.globenewswire.com/news-release/2026/06/12/3311241/0/en/lyell-immunopharma-presents-updated-safety-data-and-translational-insights-for-rondecabtagene-autoleucel-ronde-cel-in-patients-with-large-b-cell-lymphoma-at-european-hematology-ass.html · 6/12/2026+0.80
https://seekingalpha.com/article/4908231-lyell-immunopharma-inc-lyel-presents-at-stifel-2026-targeted-oncology-virtual-forum · 5/23/2026+0.20
https://seekingalpha.com/article/4891461-lyell-immunopharma-inc-lyel-presents-at-25th-annual-needham-virtual-healthcare-conference · 4/17/2026+0.00
https://seekingalpha.com/article/4879671-lyell-immunopharma-inc-lyel-presents-at-td-cowen-46th-annual-health-care-conference · 3/6/2026+0.10
https://www.zacks.com/stock/news/2808693/4-drug-biotech-stocks-rising-more-than-50-in-2025-with-room-to-grow?cid=CS-STOCKNEWSAPI-FT-analyst_blog|investment_ideas-2808693 · 12/24/2025+1.00
https://www.defenseworld.net/2025/12/07/lyell-immunopharma-nasdaqlyel-sets-new-12-month-high-heres-what-happened.html · 12/7/2025+1.00
https://www.globenewswire.com/news-release/2025/11/12/3186796/0/en/Lyell-Immunopharma-Reports-Business-Highlights-and-Financial-Results-for-the-Third-Quarter-2025.html · 11/12/2025+0.80
Lyell Immunopharma, Inc. (LYEL) is a firm specializing in T cell reprogramming, dedicated to crafting T cell therapies for individuals battling solid tumors. The company's therapeutic innovation relies on advanced technology platforms: Gen-R, an ex vivo genetic reprogramming technique engineered to counteract T cell exhaustion, and Epi-R, an ex vivo epigenetic reprogramming method designed to cultivate T cells with sustained stem-like properties. Its development pipeline features notable candidates such as LYL797, a T cell product aimed at non-small cell lung cancer and triple-negative breast cancers; LYL845, intended for a broad range of solid tumors; and NY-ESO-1, focusing on synovial sarcoma and other specific solid tumor conditions. Additionally, Lyell holds a research and development collaboration and licensing agreement with GlaxoSmithKline for the NY-ESO-1 initiative. Founded in 2018, the company's main office is situated in South San Francisco, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
